Citius Oncology, Inc.
CTOR
Positions held
Your positionsCTOR isn't in your positions.
Add it to see shares, cost, and P&L here.
Fundamentals
| Market cap | $88.31M | Enterprise value | $81.96M | Trailing P/E | — | Forward P/E | — |
| PEG | — | Price / book | 2.19 | Beta | 3.40 | Dividend yield | 0.00% |
| Revenue growth | — | Earnings growth | — | Gross margin | 74.8% | Operating margin | -6.0% |
| Profit margin | 0.0% | ROE | -126.6% | ROA | -29.1% | Debt / equity | 0.25 |
| Current ratio | 0.73 | Free cash flow | -$31.17M | Analyst recommendation | none | Mean target | $4.00 |
| 52w high | $2.25 | 52w low | $0.49 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | |
|---|---|---|---|---|---|---|
| Revenue | $1.5M | $1.7M | $3.9M | $0.0M | $0.0M | — |
| Op margin | -583.5% | -1716.2% | -133.2% | — | — | — |
| Net income | -$8.9M | -$26.6M | -$5.5M | -$5.0M | -$5.4M | — |
| Gross margin | 67.1% | 80.3% | 80.0% | — | — | — |
| Gross profit | $1.0M | $1.3M | $3.2M | — | $0.0M | $0.0M |
| Operating income | -$8.7M | -$28.6M | -$5.3M | -$4.7M | -$4.9M | — |
- Revenue -10% vs prior quarter ($1.5M vs $1.7M).
- Gross margin 67.1% (was 80.3% prior quarter).
- Operating margin expanded to -583.5%.
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Revenue | $0.0M | $0.0M | $0.0M | $0.0M |
| Op margin | — | — | — | — |
| Net income | -$24.8M | -$21.1M | -$12.7M | -$5.4M |
| Gross margin | — | — | — | — |
| Gross profit | — | — | — | — |
| Operating income | -$23.5M | -$20.6M | -$12.1M | -$4.9M |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-09-03 · Citius Pharmaceuticals to Participate in September 2026 Investor Conferences
2026-08-17 · Citius Oncology shares tumble as Q3 revenue misses forecasts despite LYMPHIR launch momentum
2026-08-14 · Citius Oncology, Inc. Reports Fiscal Third Quarter 2026 Financial Results and Provides Business Update
2026-08-14 · Citius Pharmaceuticals, Inc. Reports Fiscal Third Quarter 2026 Financial Results and Provides Business Update
2026-08-12 · Citius Oncology Expands Board with Appointment of Independent Director Jonathan Peri
2026-08-05 · Citius Oncology Reports Strong Commercial Momentum for its Cancer Treatment
Price (daily)
Full chart · RSI · MACD · patterns